Table 2 Clinical and radiological characteristics of MS patients
Patients in relapse (n = 25) | Patients in remission (n = 25) | P value | ||
|---|---|---|---|---|
Disease duration [mean(SD)] | 4.6800 (4.69) | 5.52 (5.06) | 0.545 | |
Number of relapses in the last 2 years [mean (SD)] | 1.52 (0.59) | 1.36 (0.7) | 0.385 | |
Total number of relapses [mean (SD)] | 2.6 (1.55) | 3.28 (2.05) | 0.193 | |
DMDs | Monthly methylprednisolone [n (%)] | 18 (72.0%) | 13 (52.0%) | 0.01* |
Interferon beta-1a (Avonex) [n (%)] | 0 (0.0%) | 7 (28.0%) | ||
Interferon beta-1b (Betaferon) [n (%)] | 5 (20.0%) | 1 (4.0%) | ||
Interferon beta-1a (Rebif) [n (%)] | 1 (4.0%) | 4 (16.0%) | ||
Azathioprine [n (%)] | 1 (4.0%) | 0 (0.0%) | ||
EDSS before pulse steroids [mean (SD)] | 4.08 (2.06) | _ | _ | |
EDSS after pulse steroids [mean (SD)] | 2.9400 (1.72) | 2.88 (1.29) | 0.889 | |
MRS [mean (SD)] | 0.3200 (0.63) | 0.2 (0.5) | 0.458 | |
MFIS[mean (SD)] | 7.24 (4.81) | 6.56 (4.19) | 0.596 | |
MRI lesion load [mean (SD)] | 11.0400 (6.29) | 11.0800 (5.35) | 0.980 | |